日期 2025 年 5 月 27 日
时间 11am ET
Model-Based Meta-Analysis (MBMA) has emerged as a powerful tool for integrating data across clinical trials and generating insights that efficiently inform drug development and regulatory decision-making. This webinar will unpack two distinct MBMA methodologies: modeling absolute outcomes and relative treatment effects.
Using a mix of simulated and real-world case studies, this webinar will cover:
- Choosing the Right Modeling Approach
When to apply absolute outcome vs. relative effect models based on clinical and development objectives. - Maximizing Impact with Covariates
Differentiating between prognostic and predictive covariates and how they influence model applications, plus best practices for covariate exploration. - Informing Decisions with Simulations
How MBMA-based simulations can improve trial design, support treatment comparisons, and guide go/no-go decisions. - Ensuring Model Credibility
Techniques for evaluating model fit and credibility to ensure reliable, decision-ready results. - Applying MBMA in the Real World
Case studies showing how MBMA informs regulatory submissions, product strategy, and development planning.
点击报名
Matt Zierhut, PhD MBA
Vice President, MBMA Capability Lead, Certara Drug Development Solutions
Matt 通过基于模型的荟萃分析（MBMA），推动已发表的临床结果数据融入开发决策及商业与监管策略。Matt 与临床开发团队密切合作，确保在做出最关键决策的时候，能利用 MBMA 发挥最佳影响力。
点击报名
